|
 |
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
 |
 |
|
|
a National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Democracy 2, Room 693, Bethesda, Maryland 20892-5460, USA b Division of Endocrinology, Department of Medicine, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903-0019, USA
Key Words: osteoporosis • novel therapies • RANKL • OPG • Wnt • leptin • prostaglandins • SERMs
Address for correspondence: Ronald N. Margolis, Ph.D., Division of Diabetes, Endocrinology and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, 6707 Democracy Blvd., Room 693, Bethesda, MD 20892-5460. Voice: 301-594-8819; fax: 301-435-6047. e-mail: rm76f{at}nih.gov
Advances in the treatment of osteoporosis over the past decade have resulted in the generation of novel therapeutic agents aimed at providing both anticatabolic and anabolic effects in bone. In-depth understanding of the biology of key factors regulating bone metabolism has begun to reveal new approaches to treating this costly and debilitating disease. During the next decade we will observe the development and evolution of several new classes of therapeutic targets and agents to combat this disease.
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||
 |
 |
